Outlook Therapeutics Files 8-K
Ticker: OTLK · Form: 8-K · Filed: Sep 29, 2025 · CIK: 1649989
| Field | Detail |
|---|---|
| Company | Outlook Therapeutics, Inc. (OTLK) |
| Form Type | 8-K |
| Filed Date | Sep 29, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-filing, financials, regulatory
Related Tickers: OTLK
TL;DR
OTLK filed an 8-K on 9/29/25 for other events and financials.
AI Summary
Outlook Therapeutics, Inc. filed an 8-K on September 29, 2025, reporting other events and financial statements. The company, formerly known as Oncobiologics, Inc., is incorporated in Delaware and headquartered in Iselin, New Jersey.
Why It Matters
This filing indicates routine corporate reporting, providing updates on events and financial statements for Outlook Therapeutics, Inc.
Risk Assessment
Risk Level: low — This is a standard 8-K filing for corporate events and financial statements, not indicating any immediate material changes or risks.
Key Numbers
- 001-37759 — Commission File Number (SEC file identifier for Outlook Therapeutics, Inc.)
- 38-3982704 — IRS Employer Identification No. (Tax identification number for Outlook Therapeutics, Inc.)
Key Players & Entities
- Outlook Therapeutics, Inc. (company) — Registrant
- Oncobiologics, Inc. (company) — Former company name
- September 29, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Iselin, New Jersey (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing is for reporting 'Other Events' and 'Financial Statements and Exhibits' as of September 29, 2025.
When was Outlook Therapeutics, Inc. previously known by another name?
The company was formerly known as Oncobiologics, Inc., with a date of name change on August 4, 2015.
Where are Outlook Therapeutics, Inc.'s principal executive offices located?
The principal executive offices are located at 111 S. Wood Avenue, Unit #100, Iselin, New Jersey 08830.
What is the fiscal year end for Outlook Therapeutics, Inc.?
The fiscal year end for Outlook Therapeutics, Inc. is September 30.
What is the SIC code for Outlook Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Outlook Therapeutics, Inc. is 2836, which corresponds to BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Stats: 482 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2025-09-29 17:00:33
Filing Documents
- tm2527376d1_8k.htm (8-K) — 25KB
- tm2527376d1_ex99-1.htm (EX-99.1) — 13KB
- tm2527376d1_ex99-1img01.jpg (GRAPHIC) — 17KB
- 0001104659-25-094558.txt ( ) — 228KB
- otlk-20250929.xsd (EX-101.SCH) — 3KB
- otlk-20250929_lab.xml (EX-101.LAB) — 33KB
- otlk-20250929_pre.xml (EX-101.PRE) — 22KB
- tm2527376d1_8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated September 29, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Outlook Therapeutics, Inc. Date: September 29, 2025 By: /s/ Lawrence A. Kenyon Lawrence A. Kenyon Chief Financial Officer